Health economics, pharmacoeconomics and prescriptions in dermatology;Economie de la sante, pharmaco-economie et prescriptions en dermatologie

Annales de Dermatologie et de Venereologie

Volumn 127, Issue 3, 2000, Pages 324-328

  Berdeaux, G ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EMOLLIENT AGENT; DERMATOLOGICAL AGENT;

ARTICLE; COST BENEFIT ANALYSIS; DERMATOLOGY; HEALTH ECONOMICS; PRESCRIPTION; PSORIASIS; QUALITY OF LIFE; SKIN DISEASE; ULTRAVIOLET B RADIATION; DRUG COST; ECONOMICS; FRANCE; HUMAN; PUBLIC HEALTH;

COST-BENEFIT ANALYSIS; DERMATOLOGIC AGENTS; DRUG COSTS; FRANCE; HUMANS; NATIONAL HEALTH PROGRAMS;

EID: 0034153232     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. OECD Health Data (1993, 1994, 1995). OECD Health Data, Comparative analysis of health systems (Eco-Santé, Analyse comparative des systèmes de santé). CREDES, OECD, 2, rue André-Pascal, 75775 Paris Cedex 16, France.
2. Williams A. Health economics : the end of clinical freedom ? BMJ 1988;297:1183-6.
3. Drummond M, Stoddard G, Torrance G. Methods for economic evaluation of health care programmes. Oxford : Oxford University Press, 1989.
4. Finlay AY. Psychological impact of skin disease. In : Seymour CA, Heagarty AM, eds Horizons in medecine. London : Mac Graw Hill, 1993:172-9
5. Ryan TJ. Disability in dermatology. Br J Hosp Med 1991;46:33-6.
6. Finlay AY. Quality of life in dermatology : a practical guide. Br J Dermatol 1997;136:305-14.
7. Salek MS, Finlay AY, Luscombe DK, Allen BR, Berh-Jones J, Camp RD, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double blind, placebo-controlled trial. Br J Dermatol 1993;129:422-30.
8. Finlay AY. Quality of life impairement in atopic dermatitis and psoriasis. Clin Exp Persp Sandimmun Ther 1992;2:10-11.
9. Lambert J. Economic analysis of the treatment of psoriasis. Eur J Dermatol 1996;6:543-47.
10. Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Bradham DD, Exum ML, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997;37: 564-9.
11. Fleisher AB, Rapp SR, Reboussin DM, Vanarthos JC, Feldman SR. Patient measurement of psoriasis disease severity with a structured instrument. J Invest Dermatol 1994:102:967-9.
12. Cork M. Economic considerations in the treatment of psoriasis. Dermatology in Practice 1993:16-20.
13. Einarson TR, Arikian SR, Shear N. Oral treatment for severe psoriasis : government payor analysis for Canada. J Dermatol Treat 1994;5(Suppl(i) : S23-S27.
14. Stern RS. The benefits, costs and risks of topical tar preparations in the treatment of psoriasis : considerations of cost effectiveness. Ann Acad Med Singapore, 1988;17:473-6.
15. Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A. The annual cost of psoriasis. J Am Acad Dermatol. 1993;28:422-5.
16. Arikian SR, Einarson TR. The annual cost of psoriasis. J Am Acad Dermatol 1994;30:1047-8.
17. Snellman E, Maljanen T, Aromaa A, Reunanen A, Jyrkinen-Pakkasvirta T, Luoma J. Effect of heliotherapy on the cost of psoriasis. Br J Dermatol 1998;138:288-92.